Xspray Pharma AB (publ) (STO:XSPRAY)

Sweden flag Sweden · Delayed Price · Currency is SEK
30.90
+0.10 (0.32%)
May 22, 2025, 4:51 PM CET
-44.82%
Market Cap 1.15B
Revenue (ttm) n/a
Net Income (ttm) -260.07M
Shares Out 37.14M
EPS (ttm) -7.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,396
Average Volume 20,218
Open 31.25
Previous Close 30.80
Day's Range 30.70 - 31.85
52-Week Range 23.00 - 91.70
Beta 0.64
RSI 44.43
Earnings Date May 7, 2025

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partn... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 27
Stock Exchange Nasdaq Stockholm
Ticker Symbol XSPRAY
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.